according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

#### **SECTION 1. IDENTIFICATION**

Product name : Letermovir Liquid Formulation

Other means of identification : No data available

### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

#### GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure (Oral)

: Category 2 (Liver, spleen, Blood)

#### **GHS** label elements

Hazard pictograms :

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapors.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

according to the Hazardous Products Regulations



# Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

#### Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

#### Other hazards

None known.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

### Components

Chemical name	Common CAS-No.		Concentration (% w/w)	
	Name/Synonym			
Letermovir	No data availa- ble	917389-32-3	>= 1 - < 5 *	

Actual concentration or concentration range is withheld as a trade secret

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled: : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delaved

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection.

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : A

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

according to the Hazardous Products Regulations



# Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 66853-00021 Date of first issue: 02/27/2015 3.9

> Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

Gases

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Letermovir	917389-32-3	TWA	0.4 mg/m3 (OEB 2)	Internal

Use appropriate engineering controls and manufacturing **Engineering measures** 

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material

Chemical-resistant gloves

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat. Hygiene measures

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

according to the Hazardous Products Regulations



# Letermovir Liquid Formulation

Version 3.9

Revision Date: 09/30/2023

SDS Number: 66853-00021

Date of last issue: 04/04/2023 Date of first issue: 02/27/2015

use of administrative controls.

## **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : liquid

Color : clear

Odor : odorless

Odor Threshold : No data available

pH : 7.5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 66853-00021 Date of first issue: 02/27/2015 3.9

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size Not applicable

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity Not classified as a reactivity hazard. Stable under normal conditions. Chemical stability Can react with strong oxidizing agents.

Possibility of hazardous reac- :

tions

None known. Conditions to avoid Incompatible materials Oxidizing agents

Hazardous decomposition No hazardous decomposition products are known.

products

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

**Components:** 

Letermovir:

Acute oral toxicity LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Letermovir:

Remarks No data available

Serious eye damage/eye irritation

Not classified based on available information.

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

**Components:** 

Letermovir:

Remarks : No data available

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

**Components:** 

Letermovir:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

**Components:** 

Letermovir:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, female Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility.

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 180 mg/kg body weight

Result: No effects on fertility.

Remarks: The significance of these findings for humans is not

certain.

Test Type: Fertility/early embryonic development

Species: Monkey, male Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Developmental Toxicity: LOAEL: 250 mg/kg body weight

Result: Embryo-fetal toxicity.

Remarks: Maternal toxicity observed.

Test Type: Embryo-fetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 225 mg/kg body weight Result: Embryo-fetal toxicity., Malformations were observed.,

Abortion

Remarks: Maternal toxicity observed.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

### STOT-single exposure

Not classified based on available information.

## STOT-repeated exposure

May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

#### **Components:**

#### Letermovir:

Routes of exposure : Ingestion

Target Organs : Liver, spleen, Blood

Assessment : May cause damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

# Components:

#### Letermovir:

Species : Mouse
NOAEL : 40 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

Exposure time : 13 Weeks
Target Organs : Liver, spleen

Species : Rat
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 26 Weeks

Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 100 mg/kg
LOAEL : 200 - 250 mg/kg

Application Route : Oral
Exposure time : 39 Weeks
Target Organs : Kidney

Species : Rat
NOAEL : 60 mg/kg
LOAEL : 180 mg/kg
Exposure time : 13 Weeks

Target Organs : Testis, Blood, Liver, spleen, Immune system

Species: MonkeyNOAEL: 30 mg/kgLOAEL: 100 mg/kgApplication Route: OralExposure time: 4 WeeksTarget Organs: Blood

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

### **Components:**

### Letermovir:

Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Headache, Dizzi-

ness, Fatigue, Back pain, Edema, Rash, muscle pain

## **SECTION 12. ECOLOGICAL INFORMATION**

### **Ecotoxicity**

### **Components:**

### Letermovir:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 16 mg/l

Exposure time: 96 h

according to the Hazardous Products Regulations



# Letermovir Liquid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 09/30/2023 66853-00021 Date of first issue: 02/27/2015 3.9

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 1.2 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms EC50: > 972 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 29.6 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

## Persistence and degradability

### Components:

Letermovir:

Biodegradability Result: rapidly degradable

> Biodegradation: 50 % Exposure time: 6.7 d

#### Bioaccumulative potential

#### **Components:**

Letermovir:

Partition coefficient: n-

octanol/water

: log Pow: 2.29

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

: log Koc: 3.46

Mobility in soil

**Components:** 

Letermovir:

Distribution among environ-

mental compartments

Other adverse effects

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS** 

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION** 

**International Regulations** 

**UNRTDG** 

Not regulated as a dangerous good

**IATA-DGR** 

Not regulated as a dangerous good

**IMDG-Code** 

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

**Domestic regulation** 

**TDG** 

Not regulated as a dangerous good

Special precautions for user

Not applicable

**SECTION 15. REGULATORY INFORMATION** 

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the Hazardous Products Regulations



# Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.9 09/30/2023 66853-00021 Date of first issue: 02/27/2015

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation. Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Chart

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

according to the Hazardous Products Regulations



# **Letermovir Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/04/2023

 3.9
 09/30/2023
 66853-00021
 Date of first issue: 02/27/2015

CA / Z8